Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475140 | 0.83 | KDM4E (0.32) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL1743259 | 0.71 | TLR4 (0.32) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL8054703 | 0.71 | CA1 (0.30) | — | |
| SCHEMBL1177456 | 0.70 | — | — | |
| SCHEMBL23369354 | 0.68 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL8161986 | 0.68 | MAPT (0.45) | MAPT | |
| SCHEMBL1573211 | 0.68 | APLNR (0.30) | — | |
| SCHEMBL7350816 | 0.68 | SLC6A3 (0.44) | ALDH1A1TDP1KDM4EPOLBMAPT | |
| SCHEMBL9219255 | 0.67 | CA1 (0.44) | ALDH1A1KDM4EMAPTHTT | |
| SCHEMBL170644 | 0.67 | CA1 (0.39) | ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809206-B2 | CONTACTING A PHENYL ESTER COMPOUND WITH A CYCLIC COMPOUND IN THE PRESENCE OF A SOURCE OF CYANIDE OR FLUORIDE TO PREPARE ACYLATED CYCLIC 1,3-DICARBONYL COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20030232984-A1 | Method for acylating cyclic compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20020049317-A1 | Method for acylating cyclic compounds | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049317-A1 | Method for acylating cyclic compounds | LCAT, ACOT7, AGPAT5 | ALDH1A1 3181/4885TDP1 2450/4885KDM4E 1590/4885 |
| US-20030232984-A1 | Method for acylating cyclic compounds | LCAT, ACOT7, AGPAT5 | ALDH1A1 3181/4885TDP1 2450/4885KDM4E 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.